Practical Implications of Executive Orders to Lower Costs for Prescription Drugs
This Briefing is brought to you by AHLA’s Payers, Plans, and Managed Care Practice Group.
- October 05, 2020
- Jen McDowell , Chicago, IL
On July 24, 2020, President Trump issued a series of four Executive Orders intended to lower the cost of prescription drugs for Americans. Three of the four Executive Orders were published in the Federal Register shortly after issuance:
- Executive Order 13937: Access to Affordable Life-Saving Medications, which requires pass-through 340B pricing for insulin and epinephrine;
- Executive Order 13938: Increasing Drug Importation to Lower Prices for American Patients; and
- Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen.
The fourth Executive Order, numbered 13947 and governing costs for Medicare Part B drugs, was initially withheld from publication in an attempt to prompt legislative action from Congress or voluntary price concessions from pharmaceutical manufacturers. Nearly two months after Executive Order 13947 was announced, and with no action taken in response to the President’s directive, a new Executive Order 13948 on Lowering Drug Prices by Putting America First, was issued on September 13, 2020.
You must be logged in to access this content.